vTv Therapeutics (VTVT) Debt to Equity (2016 - 2023)
Historic Debt to Equity for vTv Therapeutics (VTVT) over the last 10 years, with Q1 2023 value amounting to -$0.05.
- vTv Therapeutics' Debt to Equity rose 4950.72% to -$0.05 in Q1 2023 from the same period last year, while for Mar 2023 it was -$0.05, marking a year-over-year increase of 4950.72%. This contributed to the annual value of -$0.06 for FY2022, which is 5084.68% up from last year.
- Per vTv Therapeutics' latest filing, its Debt to Equity stood at -$0.05 for Q1 2023, which was up 4950.72% from -$0.06 recorded in Q4 2022.
- In the past 5 years, vTv Therapeutics' Debt to Equity registered a high of -$0.04 during Q4 2020, and its lowest value of -$0.13 during Q4 2021.
- For the 5-year period, vTv Therapeutics' Debt to Equity averaged around -$0.07, with its median value being -$0.06 (2022).
- Per our database at Business Quant, vTv Therapeutics' Debt to Equity soared by 7965.75% in 2019 and then plummeted by 26150.19% in 2021.
- Quarter analysis of 5 years shows vTv Therapeutics' Debt to Equity stood at -$0.05 in 2019, then surged by 32.45% to -$0.04 in 2020, then tumbled by 261.5% to -$0.13 in 2021, then surged by 50.85% to -$0.06 in 2022, then grew by 24.57% to -$0.05 in 2023.
- Its Debt to Equity was -$0.05 in Q1 2023, compared to -$0.06 in Q4 2022 and -$0.09 in Q3 2022.